Universe Pharmaceuticals (UPC)
NASDAQ:UPC
Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.00 - $11.00
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$1.62M
Enterprise Value-$22.71M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding563,338
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-14.00
Enterprise Value/Revenue-1.27
Enterprise Value/Gross Profit-3.60
Enterprise Value/Ebitda7.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stable Asset BaseConservative leverage and a modest absolute debt load give the company durable financial flexibility to fund near-term R&D or operations without immediate refinancing. Stable assets provide a reliable collateral base, lowering short-term solvency risk while management works to restore operating profitability.
Gross-margin Recovery And Improving MarginsA meaningful rebound in gross margin and narrower net losses indicate the company has begun recapturing pricing power or reducing COGS. Higher gross margins create structural leverage: as volumes stabilize, incremental revenue converts more readily to operating income, accelerating a path to sustainable profitability.
Formal Equity Incentive Plan To Retain TalentImplementing a structured equity incentive program aligns employee compensation with long-term performance and helps retain R&D and commercialization talent critical in specialty pharma. Better retention reduces execution risk on product development and commercialization initiatives over the medium term.
Bears Say
Multi-year Revenue DeclineA sustained, material revenue decline over multiple years signals structural demand weakness, possible product displacement or loss of market share. This erodes operating leverage, constrains reinvestment capacity, and makes recovery dependent on credible new product or market wins rather than short-term fixes.
Persistent Negative Cash Flow And Cash BurnOngoing negative operating and free cash flow requires continued external funding or depletion of balance sheet resources. This weak cash generation increases dilution or financing risk, limits the firm's ability to consistently fund trials, launches or commercialization, and heightens execution risk absent sustained improvement.
Concentrated CEO Voting ControlHeavy voting concentration with the CEO consolidates strategic control and can weaken minority shareholder protections. Such governance concentration raises the risk of entrenchment and may reduce accountability over capital allocation decisions during a critical turnaround phase.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $11.00 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $1.62M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 563,338 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---